Evidence map›Paper›PMID 32847852›Full record

ArticleJournal of virology2020

Ubiquitin Modification of the Epstein-Barr Virus Immediate Early Transactivator Zta.

Mengmeng Zhao, Asuka Nanbo, David Becnel, Zhiqiang Qin, Gilbert F Morris, Li Li, Zhen Lin

Abstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Sequence Analysis ofFrontiers in veterinary science · 2022
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengmeng ZhaoDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana, USA.
Asuka NanboNational Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, Japan.
David BecnelDepartment of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana, USA.
Zhiqiang QinDepartment of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Gilbert F MorrisDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana, USA.
Li LiInstitute of Translational Research, Ochsner Clinic Foundation, New Orleans, Louisiana, USA.
Zhen LinDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana, USA zlin@tulane.edu.ORCID 0000-0002-9229-053X

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Translational Genomics Core (TGC)P20GM121288 · NIGMS · LSU HEALTH SCIENCES CENTER · PI Luis Del Valle · 2017 to 2026
$22.4M
NIGMS NIH HHS P20 GM121288NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

The Epstein-Barr virus (EBV) immediate early transactivator Zta plays a key role in regulating the transition from latency to the lytic replication stages of EBV infection. Regulation of Zta is known to be controlled through a number of transcriptional and posttranscriptional events. Here, we show that Zta is targeted for ubiquitin modification and that this can occur in EBV-negative and in EBV-infected cells. Genetic studies show critical roles for both an amino-terminal region of Zta and the basic DNA binding domain of Zta in regulating Zta ubiquitination. Pulse-chase experiments demonstrate that the bulk population of Zta is relatively stable but that at least a subset of ubiquitinated Zta molecules are targeted for degradation in the cell. Mutation of four out of a total of nine lysine residues in Zta largely abrogates its ubiquitination, indicating that these are primary ubiquitination target sites. A Zta mutant carrying mutations at these four lysine residues (lysine 12, lysine 188, lysine 207, and lysine 219) cannot induce latently infected cells to produce and/or release infectious virions. Nevertheless, this mutant can induce early gene expression, suggesting a possible defect at the level of viral replication or later in the lytic cascade. As far as we know, this is the first study that has investigated the targeting of Zta by ubiquitination or its role in Zta function.

Indexed as

Cell LineEpstein-Barr Virus InfectionsGene Expression Regulation, ViralHerpesvirus 4, HumanHumansMutationPromoter Regions, GeneticProtein BindingProtein DomainsTrans-ActivatorsUbiquitinViral ProteinsVirus ReplicationBZLF1 protein, Herpesvirus 4, HumanTrans-ActivatorsUbiquitinViral ProteinsEpstein-Barr viruslytic replicationreactivationubiquitinationZta

Identifiers

PMID32847852
PMCPMC7592219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.